Cellectis SA (CLLS)
1.91
-0.07
(-3.54%)
USD |
NASDAQ |
Nov 14, 16:00
1.90
-0.01
(-0.52%)
After-Hours: 20:00
Cellectis Research and Development Expense (Quarterly): 23.83M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 23.83M |
| June 30, 2024 | 23.52M |
| March 31, 2024 | 22.32M |
| December 31, 2023 | 24.96M |
| September 30, 2023 | 19.08M |
| June 30, 2023 | 22.20M |
| March 31, 2023 | 21.42M |
| December 31, 2022 | 21.43M |
| September 30, 2022 | 23.84M |
| June 30, 2022 | 25.63M |
| March 31, 2022 | 26.60M |
| December 31, 2021 | 21.18M |
| September 30, 2021 | 34.32M |
| June 30, 2021 | 31.15M |
| March 31, 2021 | 31.00M |
| December 31, 2020 | 13.45M |
| September 30, 2020 | 20.10M |
| June 30, 2020 | 22.86M |
| March 31, 2020 | 20.72M |
| December 31, 2019 | 30.44M |
| Date | Value |
|---|---|
| September 30, 2019 | 21.60M |
| June 30, 2019 | 25.42M |
| March 31, 2019 | 14.51M |
| December 31, 2018 | 21.40M |
| September 30, 2018 | 18.69M |
| June 30, 2018 | 18.04M |
| March 31, 2018 | 18.40M |
| December 31, 2017 | 20.70M |
| September 30, 2017 | 20.29M |
| June 30, 2017 | 18.61M |
| March 31, 2017 | 19.58M |
| December 31, 2016 | 20.19M |
| September 30, 2016 | 15.43M |
| June 30, 2016 | 21.72M |
| March 31, 2016 | 21.39M |
| December 31, 2015 | 17.22M |
| September 30, 2015 | 18.18M |
| June 30, 2015 | 14.34M |
| March 31, 2015 | 8.053M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.45M
Minimum
Dec 2020
34.32M
Maximum
Sep 2021
24.00M
Average
23.19M
Median
Research and Development Expense (Quarterly) Benchmarks
| Genfit SA | -- |
| Edap TMS SA | 1.887M |
| Adaptimmune Therapeutics PLC | 40.45M |
| NuCana PLC | 8.540M |
| TC BioPharm (Holdings) PLC | 1.648M |